In KEGG analysis based on putative pleiotropic genes and potential therapeutic targets, we identified several pleiotropic pathways that have been confirmed to be shared by HF and CKD, which may also play an important role in the SGLT2 inhibitors pharmacological mechanism. The gene discussed is SLC5A2; the disease is chronic kidney disease.